Cell BioEngines announces exclusive licencing agreement for cancer cure
pharmafile | January 26, 2023 | News story | Medical Communications |
US-based cell and gene therapy company Cell BioEngines has announced its exclusive licencing agreement with Icahn School of Medicine at Mount Sinai in New York, US, for the development and worldwide commercialisation rights for differentiating most potent immune cells from stem cells and large-scale manufacturing.
Following the company’s focus of developing an allogenic cell-based product for solid tumours, Cell BioEngines will utilise Icahn Mount Sinai’s technology platform to develop discrete immune cell-based therapies which were previously inaccessible to cancer patients, such as subtypes of dendritic cells (DC), NK cells and macrophages.
Although the amount has been undisclosed, it is known that Icahn Mount Sinai will be eligible for an upfront cash payment, with additional development, regulatory and commercial milestone payments.
“Cell BioEngines is truly honoured and excited to have this opportunity to advance Icahn Mount Sinai’s discovery to offer great hope for people with cancer and position Cell BioEngines to be a key player in the immune cell-based therapeutics area. The technology platform developed in Nina’s laboratory fundamentally embraces the incredible complexity of discovering single immune cell signatures in the tumour microenvironment, building on my previous research conducted at Harvard Medical School/Broad Institute and enables us to differentiate and manufacture the most potent clusters of immune cell states in high numbers that are spatially stable and chemically configured to activate a robust response against cancer,” stated Ajay Vishwakarma, DMD, MSc, MBA, founder and CEO of Cell BioEngines Inc.
“We are delighted that the potency of conventional type I dendritic cell subsets (cDC1), a non-redundant cell subset in antitumor immunity, will be evaluated for the first time in the clinic to treat cancer patients,” said Dr Bhardwaj.
“Our immune cell generation platform can generate billions of functional dendritic cell subtypes and provide an option for developing off-the shelf cellular vaccine for cancer immunotherapy,” said Dr Balan, who invented the technology with Dr Bhardwaj.
James Spargo
